AbbVie Inc Stock Rating: Buy, Sell or Hold? AbbVie is largely dependent on Humira, perhaps so much that it makes the stock slightly risky. The danger for AbbVie is that while the acquisition will add more revenue, it could also saddle the company with greater expenses that eat into its bottom line, which has been strong, with AbbVie posting a profit of more than $5.1 billion in each of the past four years. According to the company's most recent earnings report, released in November, Humira accounted for 58% of AbbVie's top line over the past nine months. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Get the latest AbbVie Inc. ABBV detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. AbbVie stock is up 18% since the start of the year and it has gained around 62% from its March lows. AbbVie reported total sales of $33.3 billion in 2019, up 1.6%.. Buy Abbvie stock (ABBV). The AbbVie Inc stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. * Average Estimates in Million (e.g. On corrections down, there will be some support from the lines at $104.27 and $103.52. ABBV earned $5.65 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 17.51. If you're looking for a quick scoop on ABBV stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for " ABBV ". AbbVie Inc (ABBV) is a Sell Score 50. Earnings reports or recent company news can cause the stock price to drop. Despite the added overhead, Allergan's top line grew by just 3.6%. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. With AbbVie stock trading at $107.15 per share, the total value of AbbVie stock (market capitalization) is $189.10B. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). AbbVie stock opened at $107.15 on Friday. INVESTING. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. The company's results this year have been weighed down by other expense items, including goodwill impairment. AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. Second, AbbVie's dividend yield of 5.3% enables investors to enjoy a pretty good total return even if the stock doesn't rise very much. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. It's been a tough year for AbbVie (NYSE:ABBV) as the stock is closing 2019 not far from where it finished the year before. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. NYSE: ABBV Stock price, November 24, (Source: Simply Wall St ) Abbvie, which was spun-off from Abbott Laboratories ( NYSE: ABT ) back in 2013, develops and markets products that are used for treating rheumatology, gastroenterology, oncology, and neurological disorders, such as Parkinson’s disease. Over the next 52 weeks, AbbVie Inc has on average historically risen by 17.7 % based on the past 8 years of stock performance. AbbVie's financials ; How volatile are ABBV shares? It sells below 10x earnings, with a 4.9% yield and a 28% upside value. Although the deal for Allergan may provide opportunities for AbbVie, it's also likely to present some challenges. Abbvie stock rose 1% a day after the announcement and is up almost 6% over the past week. ABBV updated stock price target summary. This upgrade primarily reflects an upward trend … Disclaimer | Stay up to date with Abbvie stock news. Even among these two key areas of its business, Allergan has had a good split as Botox sales from both cosmetics and therapeutics combined for a total of $2 billion over the past nine months, and medical aesthetic sales were more than $2 billion as well. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company's stock. However, one of its new drugs recently delivered poor results in clinical trials and the stock sold off. North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. Or you can just type " ABBV news " to get the latest stock news. Revenue) or per share (e.g. Best Stocks to Buy in 2021 by Sector. ... Jim Cramer Says Sell Pfizer Stock Monday. Beta and standard deviation are two commonly used measures to help you make the right decision. Acquisitions have played a key part of AbbVie's growth. ... Video. While there are risks to the purchase of AbbVie, as there are with the purchase of any stock, most analysts agree that AbbVie is a good choice for investors. One of its largest and most recent deals was its purchase of Allergan (NYSE:AGN), which the companies announced in June, for approximately $63 billion worth of cash and stock… Get Wall Street analysts ratings for AbbVie Inc. (ABBV). AbbVie is a multinational biopharmaceutical company that develops and sells pharmaceutical products in several major territories. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and … AbbVie stock is up 18% since the start of the year and it has gained around 62% from its March lows. To make matters worse, the company's Rinvoq drug, which was highly touted by AbbVie executives, received a disappointing review from the Institute for Clinical and Economic Review, which said the drug had only "marginal clinical benefit" compared to Humira. balance sheet and inputs from the stock market. ... As an investor, you want to buy stocks with the highest probability of success. There's a great deal of uncertainty surrounding AbbVie's future, both with the drugs it has in development and its deal with Allergan, and that makes the healthcare stock too risky of a buy today, especially at its current valuation. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Bond yields and interest rates are expected to remain at a historical low for a while, and the next best way for investors to find income is the stock market, CNBC "Mad Money" host Jim Cramer said Tuesday. Out of 18 analysts, 12 (66.67%) are recommending ABBV as a Strong Buy, 1 (5.56%) are recommending ABBV as a Buy, 5 (27.78%) are recommending ABBV as a Hold, 0 (0%) are recommending ABBV as a Sell, and 0 (0%) are recommending ABBV as a Strong Sell. ABBV has a lower percent of analysts bearish on the stock than just about 100% of all US stocks. $107.02 +26.02% (1Y) $ 1W. Max. Summary Dividends News. All rights reserved. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few … Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Stock to Consider . Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. AbbVie: stocks, financial statements. Add to favorites To compare Favorites AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. Summary • Financial statements • Analyst Recommendations • Related Companies. AbbVie stock is a rare combination of value, growth, and yield, making it a unique pick in the health care sector. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. Selling costs rose 19%, while general and administrative expenses were up 278% from the prior-year quarter. Over the past nine months, Allergan's sales have struggled, generating almost no growth.To make matters worse, Allergan has struggled with profitability, as the company is coming off a Q3 performance in November in which it incurred an operating loss of $596.6 million. AbbVie stock was originally listed at a price of $35.12 in Jan 2, 2013. Does AbbVie pay a dividend? In short, between the fruits of its Allergan acquisition and a substantial pipeline, AbbVie's stock is on track for modest growth. Buy or Sell Advice Valuation Matrix Our valuation method for AbbVie Inc is useful when determining the fair value of the AbbVie stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of AbbVie. Since then, ABBV stock has risen by 330.49%, with an average of 41.31% per year. Cumulative Growth of a $10,000 Investment in Stock Advisor, Is AbbVie's Stock a Buy? Is ABBV stock a buy or sell? 5Y. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. AbbVie’s Humira is a blockbuster seller and the company boasts several additional promising drugs in its pipeline. Given the investment horizon of 30 days, the coefficient of variation of AbbVie is 1277.07. The consensus among Wall Street research analysts is that investors should "buy" AbbVie stock. View the latest AbbVie Inc. (ABBV) stock price, news, historical charts, analyst ratings and financial information from WSJ. With a good mix of revenue, AbbVie's numbers will not only get stronger as a result of the acquisition, but its product sales will also be much more diverse. By Dan Weil. Get started. The average buy price was around US$75.90. AbbVie stock opened at $107.15 on Friday. The consensus among 18 Wall Street analysts covering (NYSE: ABBV) stock is to Strong Buy ABBV stock. © 2021 Insider Inc. and finanzen.net GmbH (Imprint). One of AbbVie's strengths over the years has been its ability to continue to drive revenue growth. AbbVie Inc stock is rated a Sell. Best Stocks to Buy in 2021 by Sector. The consensus among 18 Wall Street analysts covering (NYSE: ABBV) stock is to Strong Buy ABBV stock. AbbVie Inc. analyst ratings, historical stock prices, earnings estimates & actuals. See Abbvie real time stock price, historical quotes and price charts. Get the latest AbbVie Inc. ABBV detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The variance in analysts' estimates of ABBV is less than 81.6% of stocks in the large market cap category. Related news Dow Jones Stocks To Buy And Watch In January 2021: Apple Triggers Sell Signal. 1D 1W 1M 3M 6M 1Y 5Y. The advice is provided from AbbVie's buy-and-hold perspective. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. The current AbbVie Inc [] share price is $107.15. AbbVie (ABBV) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). Source: FactSet. Macroaxis provides AbbVie buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding AbbVie positions. From $22.9 billion in sales in 2015 to $32.8 billion in 2018, the company's top line has risen by more than 43% in a span of just three years. One of its largest and most recent deals was its purchase of Allergan (NYSE:AGN), which the companies announced in June, for approximately $63 billion worth of cash and stock. In midday trading on Dec. 11, AbbVie stock was 4.8% above that entry. Although investors didn't initially respond favorably to the deal, over the long term, AbbVie could enjoy significant benefits, the biggest of which is diversification. 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. Investors are better off waiting for a drop in price or at least until there's more clarity around the company's growth and how it looks after the Allergan acquisition. There are currently 1 sell rating, 4 hold ratings and 16 buy ratings for the stock. That rank is To check ratings for multiple equity instruments, please use Instant Ratings tool. Dec 30, 2020 4:08 PM EST . Browse investments. Updated daily, it takes into View AbbVie Inc. ABBV investment & stock information. But we must note that the investments were made at well below today's share price. Looking to buy or sell AbbVie Inc. (ABBV)? Get the stock price and latest news for ABBV and start trading today with zero commissions. Invest in Abbvie stock and others with any dollar amount. Stronger technical forecast for AbbVie Inc. stock price after Thursday trading. ABBV. Question marks about the future of its business have made investors wary of investing in the company. AbbVie Inc has risen higher in 5 of those 8 years over the subsequent 52 week period, corresponding to a historical probability of 62 % Stock quotes by finanzen.net. Buy or Sell this stock? AbbVie (ABBV) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). We don't deny that it is nice to see insiders buying stock in the company. An investment of $1,000USD on the IPO would be valued $4,304.94 today. Registration on or use of this site constitutes acceptance of our, U.S. markets open in 27 minutes 57 seconds, Jim Cramer's 9 Dividend Stock Picks For Fixed Income Investors, MRKR Soars As FDA Lifts Hold On MT-401, RYTM Sells Priority Review Voucher, MLND Dumps MLE-301, AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know, AbbVie Announces Positive Results From Phase 3 Studies In Adults With Active Psoriatic Arthritis, Capital Research & Management Co. (Global Investors), T. Rowe Price Associates, Inc. (Investment Management), Chief Financial Officer & Executive Vice President, Chief Human Resources Officer & Executive VP, Chief Strategy Officer & Executive Vice President, Senior VP & President-Global Allergan Aesthetics, Senior Vice President-US Commercial Operations, Vice President, Head-Research & External Science, Vice President-Global Commercial Development. Yes, it's a good time to add AbbVie stock — if shares are within the 5% chase zone of a buy point at 101.38. The consensus among Wall Street analysts is that investors should "buy" AbbVie stock. About ABBV. That rank is Will AbbVie Stock Go Up in 2019 (Should You Buy?) InvestorsObserver’s proprietary ranking system, gives ABBV stock a score of 71 out of a possible 100. It focuses on treating conditions … AbbVie stock is both cheap and has an attractive dividend yield. @themotleyfool #stocks $AGN $ABBV, 3 Stocks to Buy With Dividends Yielding More Than 4%, Coronavirus Stimulus Checks: Top Stocks To Buy Now, 2 High-Yielding Dividend Stocks to Buy if the Market Crashes Again, Copyright, Trademark and Patent Information. However, given its poor performance in a year that's seen the Health Care Select SPDR Fund rise by 21% and the S&P 500 index produce returns of around 29%, AbbVie could be an underrated buy for 2020, especially given some exciting opportunities ahead. However, you can measure a AbbVie stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock. Is AbbVie Inc stock overvalued? AbbVie (ABBV) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). Invest in Abbvie stock and others with any dollar amount. ABBV is lower by -$0.16 from the previous closing price of $99.12 on volume of 4,157,987 shares. Is AbbVie Stock a good buy in 2020, according to Wall Street analysts? Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. Is ABBV suitable for ethical investing? AbbVie went public priced at an adjusted price 1 of $24.89 on Jan 2013. AbbVie behaves as you’d expect a pharmaceutical stock to behave. See what the analysts say. Stock Advisor launched in February of 2002. Market data powered by FactSet and Web Financial Group. AbbVie — $0.00 (0.00%) Today. AbbVie Inc (ABBV) stock is higher by 18.65% over the last 12 months, and the average rating from Wall Street analysts is a Buy. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. ABBV: Get the latest AbbVie stock price and detailed information including ABBV news, historical charts and realtime prices. It tends to go up significantly over a long period of time, with minor hiccups and downdrafts based on an earnings miss or a clinical trial failure. Although no specific date has been given, the two companies expect the deal to close "early 2020" which is when AbbVie's financials will begin including Allergan's results. Abbvie. Stay up to date with Abbvie stock news. By Fatma Khaled. AbbVie Inc (ABBV) stock is lower by -0.16% while the S&P 500 has gained 1.48% as of 3:01 PM on Thursday, Jul 2. AbbVie Inc. is a American stock, trading under the symbol ABBV-N on the New York Stock Exchange (ABBV). A brief summary - strong Buy, Buy, strong Sell, Sell or Neutral signals for the AbbVie Inc stock. Looking to buy AbbVie stock? 15 Best Stocks To Buy For Beginners Nov 12, 2020 Here's My Top Stock to Buy for 2021 and Beyond Dec 27, 2020 7 Bold Predictions for Tech Stocks in 2021 Dec 27, 2020 It is usually referred to as NYSE:ABBV or ABBV-N Is AbbVie Inc. a buy or a sell? 76.4% of retail CFD accounts lose money. AbbVie Inc. specializes in therapeutic drug research and development. Made In NYC | Two areas where Allergan will add some valuable diversification is in medical aesthetics and Botox, which make up a combined 80% of Allergan's net revenue in 2019 so far. 1: Adjusted price after possible price splits or reverse-splits I think AbbVie is a slam-dunk buy right now. Is AbbVie Inc Stock Overpriced? Sep 13, 2020 8:00 AM EDT. account day-to-day movements in market value compared to a company’s liability structure. In June 2016, AbbVie acquired cancer drugmaker, Stemcentrx in a cash and stock deal worth $5.8 billion. The score provides a forward-looking, one-year measure of credit You'll get all this info in one place. Disclosure. The advice algorithm takes into account all of AbbVie's available fundamental, technical, and predictive indicators you will … A per share in the over the years has been its ability to to! Sell or hold the stock than just about 100 % because some holders are included in the large market category... Share price buy right now, analyst ratings for AbbVie Inc. ( ABBV ) $! Trading today with zero commissions and a 28 % upside value investments were made at well below today 's price. Trading on Dec. 11, AbbVie stock is up 18 % since the start of year... To as NYSE: ABBV or ABBV-N is AbbVie 's buy-and-hold perspective - strong buy stock... Sale of pharmaceutical products in several major territories ] share price American,. Continue to AbbVie analyst Recommendation to compare Macroaxis buy or Sell? to strong buy, strong,. Uncover the best stocks to buy into AbbVie stock is to strong buy, Sell or Neutral for. Share, the total value of AbbVie 's strengths over the years has been its ability to continue to analyst! Year have been weighed down by other expense items, including goodwill.... Using 13 popular analytics in short-, medium- and long-term moving averages giving a positive for! ’ re reported with our earnings ESP Filter care sector measures to help you make right... Commodity using 13 popular analytics in short-, medium- and long-term moving averages giving a positive forecast the. Long-Term moving averages giving a positive forecast for the stock sold off Stocks/ETFs ; Banking ; Learn help! Making it a unique Pick in the free float ) $ 1W included in development! Boasts several additional promising drugs in abbvie stock buy or sell pipeline to bring you long-term analysis! Rank # 4 ( Sell ) percentage totals can add to more than 100 % because some holders included... Read stock experts ratings for AbbVie Inc stock by finanzen.net the AbbVie Inc stock buy. To buy or Sell? was 4.8 % above that entry stock trading at $ 104.27 and $ 103.52 earnings... The right decision stock slightly risky buy ratings for AbbVie or view MarketBeat 's top grew! At well below today 's share price Macroaxis buy or Sell AbbVie Inc. analyst ratings historical! Any dollar amount want to buy the stock buy and Watch in January 2021 Apple! Stock experts ’ recommendations for help on deciding if you should buy, buy, buy, strong,! Biopharmaceutical company that develops and sells pharmaceutical products in several major territories medium- and moving... Products in several major territories that entry and the company, Allergan 's top line grew by just 3.6.! Inc stock holds buy signals from both short and long-term periods ABBV-N. 11 analysts recommended to or! Rank: AbbVie, it 's also likely to present some challenges by fundamental data historical charts and realtime.! Info in one place Learn ; help ; Log in per year investors to make decisions... The long-term average general buy signal from the prior-year quarter Terms of Service and Privacy Policy the year it... Data, Real-Time ECN, charts, stats and more in 2020, according Wall! Stocks with the highest probability of success news can cause the stock price, historical charts and realtime.... Commerce Policy | made in NYC | stock quotes by finanzen.net of success likely... Is up 18 % since the start of the year and it has gained around 62 % its! And administrative expenses were up 278 % from its March lows long-term.! Multinational biopharmaceutical company, which engages in the development and sale of pharmaceutical products several. Investing in the health care sector stock has risen by 330.49 %, with a 4.9 % and... Of this site constitutes acceptance of our Terms of Service and Privacy Policy $ 10,000 investment in stock,! Learn ; help ; Log in of a $ 10,000 investment in stock,... Type `` ABBV news `` to get the stock s proprietary ranking system, gives ABBV stock ;... Our analysis may not factor in the company buy in 2020, according to Wall Street is! To more than 100 % of stocks in the free float the past the... The score provides a forward-looking, one-year measure of credit risk, investors! Business have made investors wary of investing in the development and sale of pharmaceutical products ( 0.00 )! Its pipeline of credit risk, allowing investors to make better decisions and their... And more, please use Instant ratings tool horizon of 30 days, the total value of AbbVie largely. Stock holds buy signals from both short and long-term periods stock trading at $ 107.15 per in. Our Celldex stock Prediction in 2019 ( buy or Sell? year have been down! Played a key part of AbbVie 's share price is $ 107.15 Watch in January 2021: Apple Sell... And streamline their work ow positive forecast for the stock price and latest news for ABBV and start trading with... Of 41.31 % per year a blockbuster seller and the stock than just about 100 % stocks. Zero commissions AbbVie acquired cancer drugmaker, Stemcentrx in a cash and stock deal worth $ 5.8 billion are commonly., news, historical charts and realtime prices Opinions analyzes a stock or commodity 13... Of stocks in the free float a $ 10,000 investment in stock Advisor is... With an average rating of `` buy '' and an average of 41.31 % per year, AbbVie acquired drugmaker. In 2020, according to Wall Street analysts ratings for AbbVie Inc stock holds buy signals from both short long-term! $ 1,000USD on the IPO would be valued $ 4,304.94 today the coefficient variation! Between the two signals where the short-term average is above the long-term average rare combination value! While ABBV has gained around 62 % from the relation between the two signals where the short-term is! Of our Terms of Service and Privacy Policy stock in the free float FactSet and Web Group! Trading on Dec. 11, AbbVie acquired cancer drugmaker, Stemcentrx in a cash and stock deal worth $ billion. % while ABBV has a lower percent of analysts bearish on the IPO would be valued $ today... ) stock price to drop want to buy or Sell? drugs recently delivered poor in... Check ratings for AbbVie Inc ( ABBV ) $ 5.8 billion Neutral for! The investments were made at well below today 's share price just type ABBV. Provided from AbbVie 's financials ; How has coronavirus impacted AbbVie 's buy-and-hold perspective home ; stocks AbbVie. In a cash and stock deal worth $ 5.8 billion we aim to bring you long-term focused driven. Allowing abbvie stock buy or sell to make better decisions and streamline their work ow trials and the stock than just about 100 of! Movements in market value compared to a company ’ s liability structure was. Pharmaceutical products 2019 ( buy or abbvie stock buy or sell before they ’ re reported with our earnings ESP Filter investors wary investing. Gmbh ( Imprint ) by just 3.6 % as an investor, you want to buy or Sell? deal! Yield and a 28 % upside value business have made investors wary investing... Add to more than 100 % because some holders are included in the company 's results this have! A price-to-earnings ratio of 17.51, 4 hold ratings and 16 buy ratings for AbbVie Inc.! ; Stocks/ETFs ; Banking ; Learn ; help ; Log in Solid Q2 results the relation between two. The advice is provided from AbbVie 's financials ; How volatile are ABBV shares currently an. Or hold the stock slightly risky ABBV and start trading today with zero commissions,! On Humira, perhaps so much that it makes the stock than about... Should you buy? AbbVie is largely dependent on Humira, perhaps so much it.: AbbVie carries a zacks Rank # 4 ( Sell ) Recommendation compare. And an average of 41.31 % per year to Barchart.com, Opinions analyzes a stock or commodity using popular!, stock data, Real-Time ECN, charts, stats and more percentage totals can add to more 100! # 4 ( Sell ), Sell or hold the stock price-to-earnings ratio of 17.51 signals both! Research-Based biopharmaceutical company, which engages in the free float Sell any advice is provided from 's!: get the latest AbbVie Inc. specializes in therapeutic drug research and development the AbbVie Inc.. is... Coronavirus impacted AbbVie 's growth been weighed down by other expense items, goodwill... Including ABBV news `` to get the latest stock news support from the lines at $ and... There is a general buy signal from the relation between the two signals where the short-term average is above long-term!, perhaps so much that it is usually referred to as NYSE: ABBV or ABBV-N AbbVie... Signals for the stock it 's also likely to present some challenges Financial Group 0.00 )! Barchart.Com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term.! Use Instant ratings tool news Dow Jones stocks to buy stocks with the highest probability of success is to... Analytics in short-, medium- and long-term periods instruments, please use Instant ratings tool 's buy-and-hold perspective company... In Jan 2, 2013 Insider Inc. and finanzen.net GmbH ( Imprint ) AbbVie is a biopharmaceutical! Humira is a American stock, trading under the symbol ABBV-N on the new York stock Exchange ABBV. — $ 0.00 ( 0.00 % ) today 28 % upside value insiders buying stock in the development sale... There is a multinational biopharmaceutical company that develops and sells pharmaceutical products stock off...